|
Q3 FY2026
As of Jul 31, 2026
|
Q2 FY2026
As of Apr 30, 2026
|
Q1 FY2026
As of Jan 31, 2026
|
Q4 FY2025
As of Oct 31, 2025
|
Q3 FY2025
As of Jul 31, 2025
|
Q2 FY2025
As of Apr 30, 2025
|
Q1 FY2025
As of Jan 31, 2025
|
Q4 FY2024
As of Oct 31, 2024
|
Q3 FY2024
As of Jul 31, 2024
|
Q2 FY2024
As of Apr 30, 2024
|
Q1 FY2024
As of Jan 31, 2024
|
Q4 FY2023
As of Oct 31, 2023
|
Q3 FY2023
As of Jul 31, 2023
|
Q2 FY2023
As of Apr 30, 2023
|
Q1 FY2023
As of Jan 31, 2023
|
Q4 FY2022
As of Oct 31, 2022
|
Q3 FY2022
As of Jul 31, 2022
|
Q2 FY2022
As of Apr 30, 2022
|
Q1 FY2022
As of Jan 31, 2022
|
Q4 FY2021
As of Oct 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS | ||||||||||||||||||||
| Cash and cash equivalents (Note 15) | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash (Note 14) | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Accounts receivable (Note 5) | ||||||||||||||||||||
| Prepaid expenses and deposits | ||||||||||||||||||||
| Due from related party (Note 7) | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total due from related party (Note 7) | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Value-added tax receivable, net of allowance for uncollectible taxes of $592,217 and $547,483, respectively (Note 8) | ||||||||||||||||||||
| Office and mining equipment, net (Note 9) | ||||||||||||||||||||
| Property concessions (Note 8) | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIENCY | ||||||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued liabilities and expenses (Notes 5 and 15) | ||||||||||||||||||||
| Income tax payable | ||||||||||||||||||||
| Loan payable (Notes 10 and 18) | ||||||||||||||||||||
| Warrant derivative liability (Note 13) | ||||||||||||||||||||
| Loan payable (Note 9) | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Warrant derivative liability (Note 14) | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| STOCKHOLDERS’ DEFICIENCY (Notes 11, 12 and 13) | ||||||||||||||||||||
| Common stock, $0.01 par value; 150,000,000 shares authorized, 49,337,882 and 49,292,882 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total Stockholders’ Deficiency | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY | ||||||||||||||||||||
Loading...
